Background High-dose-rate brachytherapy (HDR-BT) and external-beam radiation therapy (EBRT) are two modalities used in the treatment of soft tissue sarcoma. Previous work at our institution showed early complications and outcomes for patients treated with HDR-BT, EBRT, or a combination of both radiation therapy modalities. As the general indications for each of these approaches to radiation therapy differ, it is important to evaluate the use of each in an algorithmic way, reflecting how they are used in contemporary practice at sites that use these treatments.
Introduction
Before the 1980s, extremity soft tissue sarcoma treatment included surgery, often in the form of amputation [10, 60] . The addition of radiation therapy to the management of these neoplasms has shown that limb-sparing surgery combined with radiation therapy achieves similar diseasefree and overall survival profiles when compared with amputation alone [49, 64] . As such, a new era of limbsalvage surgery combined with radiation therapy has emerged as the mainstay of extremity soft tissue sarcoma treatment.
Many studies have established the efficacy of surgery and radiation for local control of extremity soft tissue sarcomas, with numerous series obtaining local control in greater than 80% of patients [2, 3, 6, 17, 21-23, 28, 32, 35, 36, 38, 41, 52, 56, 61, 62] . Preoperative, intraoperative, and postoperative radiation therapy, administered by multiple delivery methods, have been described in the treatment of soft tissue sarcomas [1, 2, 5-9, 11, 12, 14-17, 19, 24, 26, 27, 29, 32, 33, 35-37, 40, 42-46, 55, 57, 60, 61, 63] . As the risk profile and utility of each modality are variable, no one radiation therapy approach has been shown to be consistently superior regarding local control [19, 55] . As such, the preferred delivery mode, technique, and timing of radiation therapy in the management of extremity soft tissue sarcomas remain debated [2, 3, 17, 25, 27, 40, 41, 61] .
External-beam radiation therapy (EBRT) and highdose-rate brachytherapy (HDR-BT) are well-established modalities for the delivery of therapeutic radiation (5, 17, 31, 43, 44, 57, 58] in patients with an extremity soft tissue sarcoma. Complications associated with perioperative radiation therapy are common, ranging from 6% to 75% of patients so treated [11, 15, 17, 27, 33, 37, 46] , and include acute and subacute complications such as seroma, infection, and wound and long-term complications such as tissue fibrosis, contractures, and late fracture. A previous study from our institution regarding the complications associated with HDR-BT and EBRT showed a higher rate of deep infection treated by surgical débridement and/or antibiotic treatment in patients treated with HDR-BT compared with EBRT, and a higher risk of late side effects in the EBRT group, including chronic edema, fibrosis, chronic radiation dermatitis, and fracture [17] . At that time, limited followup of the HDR-BT group precluded meaningful analysis of local control or the long-term morbidity associated with brachytherapy.
Numerous studies regarding HDR-BT alone and in combination with EBRT in extremity soft tissue sarcomas are limited to retrospective analyses of small heterogeneous treatment groups that include low-and intermediategrade tumors and often lack meaningful functional analysis or outcome scores. These studies have reported high variability in local control rates of extremity soft tissue sarcoma treated with brachytherapy, ranging from 18% to 79% [22, 26, 28, 29, 34, 42, 43, 54] . The American Brachytherapy Society, whose 2013 published guidelines support the use of brachytherapy as an acceptable modality for treatment of extremity soft tissue sarcoma alone or in conjunction with EBRT, could not recommend one particular treatment strategy [25] . Additional information regarding complications, local control rates, and long-term morbidity associated with the use of brachytherapy could guide radiation therapy choice in the treatment of extremity soft tissue sarcomas.
The purposes of this study were to: (1) determine the proportion of patients with intermediate-and long-term complications associated with the use of HDR-BT, EBRT, and HDR-BT+EBRT in the treatment of primary highgrade extremity soft tissue sarcomas; and (2) characterize the long-term morbidity of the three radiation treatment groups using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer (RTOG/EORTC) Late Radiation Morbidity Scoring Scheme [13] . Finally, (3) we wanted to document that our algorithmic use of the radiation in combination with limb-salvage surgery, results in good local control in this high-risk group of sarcomas. While direct comparison among groups is not possible because of our algorithmic approach inherently making each group dissimilar, we aim to provide recommendations regarding radiation therapy strategy based on our local control, complication, and functional outcome results.
Patients and Methods
The institutional review board of our institution approved this study's human subjects protocol but did not require patient consent owing to the minimal risk, retrospective nature of the study.
We retrospectively evaluated data on 436 adult patients with high-grade extremity soft tissue sarcomas who were treated with surgical excision and radiation therapy at our institution between 1990 and 2012. Indications for surgery, radiation, and subsequent inclusion in our study included complete histologic, surgical, clinical, and radiation therapy data, an appendicular tumor location, ability to perform limb-salvage surgery, and high-grade histology. Staging according to American Joint Commission on Cancer was performed. We excluded 265 patients with soft tissue sarcomas owing to axial tumor location, previous radiation to the affected extremity, incomplete patient records, patients receiving primary amputation, recurrent tumors, pediatric patients, low-and intermediate-grade tumors, rhabdoid histology, and patients unable to tolerate surgery owing to medical comorbidities or advanced disease state. We identified 171 patients who met the inclusion criteria above with a mean duration of followup of 71.8 months. Fifteen patients (9%) were lost to followup for any reason including died of disease or other causes during the first 12 months postoperatively. This included four patients who received HDR-BT (12%), 11 who received EBRT (9%), and none who received HDR-BT+EBRT (0%) with less than 12 months followup.
Forty-three (25%) patients were treated with brachytherapy alone or in combination. Thirty-three (19%) patients were treated with HDR-BT alone, 128 (75%) with EBRT (10 patients with preoperative EBRT and 118 patients with postoperative EBRT), and 10 (6%) with combination therapy (HDR-BT + EBRT) ( Table 1) . Sixtyfive (38%) patients had a histologic diagnosis of a highgrade pleomorphic undifferentiated sarcoma, 40 had a liposarcoma (23%), 21 (12%) had a leiomyosarcoma, 14 (8%) had a synovial sarcoma, and 13 (7%) had a myxofibrosarcoma/myofibroblastic sarcoma ( Table 2) . Of the 171 patients presenting with primary disease, 124 (73%) received their index oncologic surgery at our institution and 47 (27%) received their definitive oncologic surgery (tumor bed excision) at our institution after an unplanned excision before referral. Although there were no observable differences among the three treatment groups with respect to age, sex, duration of symptoms, tumor location, or stage at presentation (Table 1) , the algorithmic approach to assigning treatment limits direct comparison of the groups. Five (15%) patients had positive margins in the HDR-BT group, 11 (9%) had positive margins in the EBRT group, and one (10%) had a positive margin in the combination therapy group.
There were no differences between the HDR-BT and EBRT groups with respect to patient age, sex, duration of symptoms, tumor volume, or tumor depth. The patients receiving HDR-BT therapy received less total radiation, had a shorter duration of treatment, and were followed up for a shorter duration than patients undergoing EBRT.
The mean duration of radiation treatment was 6.3 days in the HDR-BT group, 54.6 days in the EBRT group, and 43.1 days in the HDR-BT+EBRT group. The mean radiation therapy dose was 34.3 Gy (range, 21.6-60.0 Gy) in the HDR-BT group, 62.5 Gy (range, 39.6-72.0 Gy) in the EBRT group, and 67.6 Gy (range, 50.0-95.0 Gy) in the HDR-BT+EBRT group. There was a shorter duration of treatment (HDR-BT vs EBRT treatment duration: 6.3 6 5.9 days versus 54.6 6 24.1 days, mean difference, (18) 3 (10) 22 (19) 3 (30) Deceased of natural causes 21 (13) 3 (10) 18 (15) 0 (0) HDR-BT = high-dose-rate brachytherapy; EBRT = external-beam radiation therapy. 3 ) for the HDR-BT+EBRT group. Seventeen patients (10%) had a positive surgical margin, with five (15%) positive margins in the HDR-BT group, 11 (9%) in the EBRT group, and one (10%) in the HDR-BT+EBRT group. Primary closure was achieved in 157 patients (92%), with five patients (3%) requiring a split thickness skin graft and nine (5%) requiring a soft tissue flap and split thickness skin graft.
Determination of radiation therapy technique for each patient was individualized in a multidisciplinary forum of sarcoma specialists. Preoperative indicators that influenced radiation therapy choice include tumor grade, size, and location (particularly in relation to the neurovascular bundle and bone), anticipated positive or close surgical margin, and need for secondary or staged procedures (including soft tissue coverage procedures and vascular reconstruction). Anticipated close or positive surgical margins and a low likelihood of complex soft tissue procedures were factors that encouraged use of brachytherapy, whereas the anticipated need for secondary procedures and/or soft tissue coverage encouraged use of EBRT alone. Combination therapy was used when the treatment volume exceeded the treatment field of the brachytherapy catheters or when the catheters were used to boost a close or positive surgical margin. All patients treated with brachytherapy received care from a single radiation oncologist (MK) with specialization in brachytherapy. As such, some radiation therapy choices were affected by insurance variability, patient preference, and proximity to the treatment center. When such obstacles existed, the multidisciplinary recommendation for use of brachytherapy was not carried out and EBRT was used instead.
All patients were treated with either wide local excision or focal marginal excision with preservation of vital neurovascular structures. All operative procedures were completed by one of three fellowship-trained orthopaedic oncologic surgeons (SC, JDP, HTT) at a single institution. Resections were completed and ink used to mark margins of the excision. Frozen and permanent sections were analyzed by the pathology laboratory to determine margin status. Brachytherapy catheters were implanted intraoperatively immediately after surgical excision and subsequently loaded, on average, 5 days after placement (range, 0-10 days). EBRT was given preoperatively or postoperatively with three-dimensional conformal radiation therapy and more recently with intensity-modulated radiation therapy, in accordance with previously described techniques [17, 18, 20] .
Patients were seen daily during their hospitalization and those who received HDR-BT were seen twice daily during their treatments until the catheters were removed. All patients were seen at 1 to 2 weeks postoperatively for wound evaluation and subsequently evaluated at 1 and 3 months after surgery, or more often as needed. Baseline MRI of the involved extremity was obtained 6 weeks after completion of radiation therapy and at 3-month intervals after baseline for the first 2 years, then every 6 months for 3 to 5 years postoperative, and finally annually thereafter.
For the purposes of evaluation of the sequelae of radiation therapy, reporting on complications was limited to those locally related to the surgery and radiation. Cardiac events and pulmonary embolisms were not included in the reporting for this study. Complications were defined as immediate (< 90 days), intermediate (90 days to 2 years), or long term (> 2 years) based on when they occurred.
Complications were recorded as either major or minor. Any complication that did not require operative intervention was deemed a minor complication that was successfully managed by nonoperative means (oral antibiotics, local 
wound care). Indications for return to the operating room for irrigation and débridement were based on clinical evaluation and parameters such as inflammatory markers, continued drainage, and wound dehiscence on a case by case basis. The description, distribution, and timing of the complications were analyzed for each group (Table 3) . Patient-specific morbidity was assessed at the time of final followup using the RTOG/EORTC Late Radiation Morbidity Scoring Scheme, specifically focusing on the morbidity grades related to the skin, subcutaneous tissue, bone, and joint [13] . Each area is assessed for morbidity on a 5-point scale based on objective physical findings, with Grade 0 representing the absence of morbidity and Grade 5 indicating death directly related to the morbidity. Higher total scores indicate increasing overall morbidity [13, 16] .
Data were retrospectively collected from the patients' medical records from 1990 to 2012 and entered in an Excel ® (Microsoft Corporation, Redmond, WA, USA) database. The data were coded, cleaned, and transferred to a database in IBM SPSS, Version 22.0 (IBM Corporation, Armonk, NY, USA) for analysis. Continuous variables were tested for normality of distribution using the Kolmogorov-Smirnov and Shapiro-Wilks tests. Student's t-test was used to compare parametric continuous variables and the Mann-Whitney U test was used to compare nonparametric continuous variables. Continuous data are presented as mean 6 SD or median where appropriate. Pearson's chi-square or Fisher's exact test were used to compare categorical variables.
No patients were recalled specifically for this study. All data collection was performed with imaging studies and medical records review.
Results
One hundred thirty-one patients (77%) experienced a complication, with 31 (18%) experiencing a major complication and 100 (58%) experiencing a minor complication. Twentyfour patients (73%) in the HDR-BT group had complications, of which 16 (48%) were minor and eight (24%) were major. Eight patients (80%) in the HDR-BT+EBRT group had complications, of which four were minor and four were major. Ninety-nine (77%) patients in the EBRT group experienced complications, of which 80 (63%) were minor and 19 (15%) were major. In the HDR-BT group, 19 patients (79%) experienced complications during the immediate postoperative period, with only four patients (17%) experiencing complications during the intermediate period, and no patients (15) 1 (4) 18 (18) 1 (13) HDR-BT = high-dose-rate brachytherapy; EBRT = external-beam radiation therapy. Late morbidity was determined using the RTOG/ EORTC Late Radiation Morbidity Scoring Scheme, with higher scores indicating increased morbidity [13] . The mean RTOG/EORTC scores were 0.8 for the HDR-BT group (median, 0.0; range, 0-4), 1.9 for the EBRT group (median, 1.0; range, 0-9), and 1.7 the HDR-BT+EBRT group (median, 1.50; range, 0-5).
Twenty-seven patients (16%) had local recurrence, with the mean time to local recurrence of 26.2 months. Local recurrence occurred in six patients (18%) in the HDR-BT group, 18 (14%) in the EBRT group, and three (30%) in the HDRBT+EBRT group. At final followup, 106 (66%) patients were alive without disease, five (3%) were alive with disease, 28 (18%) had died of disease, and 21 (13%) were deceased from other causes. In the HDR-BT group, 25 (80.6%) patients were alive without disease, three (10%) had died of disease, and three (10%) died of other causes. In the EBRT group, 74 (62%) patients were alive without disease, five (4%) were alive with disease, 22 (19%) had died of disease, and 18 (15%) had died of other causes. In the HDR-BT +EBRT group, seven patients (70%) were alive and disease free and three (30%) had died of disease. At 3 years, 123 (72%) patients were still being followed. Twenty-two (67%) of the patients who had HDR-BT were alive and returned for followup at this time versus 95 (74%) patients who received EBRT, and six (60%) patients who received combination therapy. Of these, 102 (83%) overall were free from local recurrence, including 18 (82%) in the HDR-BT group, 80 (84%) in the EBRT group, and four (67%) in the combination therapy group.
Discussion
The addition of radiation therapy to limb-salvage surgery in the management of extremity soft tissue sarcoma achieves similar disease-free and overall survival profiles when compared with amputation alone [49, 64] . With a variety of effective radiation therapy techniques, the preferred strategy in the treatment of extremity soft tissue sarcoma remains debated [1, 2, 5-9, 11, 12, 14-17, 19, 24, 26, 27, 29, 32, 33, 35-37, 40, 42-46, 55, 57, 61, 64] . The ideal radiation therapy modality would minimize local recurrence and complications while maintaining limb function. Brachytherapy, in the treatment of extremity soft tissue sarcoma, is one technique that aims to improve the precision of radiation therapy to minimize morbidity and improve function [25, 35, 43) . However, the best recommendation regarding use of HDR-BT alone or in conjunction with EBRT in the management of extremity soft tissue sarcomas remains unclear owing to limited published data regarding the use of HDR-BT alone or in combination with EBRT [7, 8, 12, 26, 29, 34, 35, 41, 42, 45] . Therefore, the purpose of our study is to describe the experience at our institution to determine rates of intermediate-and long-term complications associated with the use of HDR-BT, EBRT, and combination radiation therapy in the treatment of primary high-grade extremity soft tissue sarcomas This study has several limitations. Use of a complex and intentional treatment algorithm for stratifying patients in the treatment groups and retrospective nature of the study limit meaningful direct comparative analysis among groups owing to the inherent selection bias. Future studies should compare this algorithmic approach with other possible approaches used at other institutions. Furthermore, the observed variability among groups is concordant with the treatment algorithm; with an observed high percentage of patients with positive margins and a low incidence of soft tissue coverage procedures in the HDR-BT group, and the largest tumor volumes in the HDR-BT+ EBRT group. Another limitation is that we had 15 patients (9%) who were lost to followup for any reason including those who died of disease or other causes during the first 12 months postoperatively. This included four patients (12%) in the HDR-BT group, 11 (9%) in the EBRT group, and none (0%) in the HDR-BT+EBRT group with less than 12 months followup. This loss to followup data could cause us to underestimate the true number of complications, however, the differences among groups are relatively small. Finally, the RTOG is just one way to evaluate outcomes, and future studies should consider using the Musculoskeletal Tumor Society or Toronto Extremity Scores to evaluate functional outcomes.
One purpose of this study was to determine the rates of intermediate-and long-term complications associated with the use of brachytherapy in the treatment of high-grade extremity soft tissue sarcomas.
Studies reporting complications associated with HDR-BT generally have been limited by underreporting, small sample sizes, and heterogeneous treatment groups [1, 3, 12, 14, 24, 29, 35] , making clinical application of the data challenging. As results reported by Emory et al. [17] indicated that the treatment of extremity soft tissue sarcomas with brachytherapy may result in lower long-term morbidity, we surmised that followup would confirm this trend. Few studies have investigated the long-term morbidity and functional outcomes associated with extremity soft tissue sarcomas [51, 64] .
Our study confirms that complications associated with radiation in the treatment of primary high-grade extremity soft tissue sarcomas are extremely common, occurring in more than 75% of this study population and occurring across all treatment groups. Brachytherapy, used alone or in combination with EBRT, is associated with a high number of immediate complications. Seventy-five percent of the immediate complications were manageable without return to the operative suite. Consistent with earlier reported HDR-BT results [17] , the current study confirms that the observed paucity of long-term complications in the HDR-BT group persist with a 4-year average followup. The EBRT group had the poorest RTOG scores, which correlates with the observed high incidence of chronic soft tissue complications in this group, with high rates of chronic edema, fibrosis, dermatitis, and late pathologic fracture all contributing to the poor morbidity scoring. The brachytherapy group is clinically evaluated more frequently than the EBRT group during the initial postoperative period owing to the nature of the brachytherapy treatment and daily exposure to the treating physician, which may lead to increased detection and also early treatment of acute complications. The higher mean radiation doses in the EBRT group may explain the higher rate of complications [4, 17, 41, 59] . These data support the contention that HDR-BT concentrates the dose of radiation exposure to the surgical bed and immediate surrounding tissue, potentially sparing a greater amount of tissue and the skin from radiation-induced side effects [4, 17, 41, 59] . Regardless of the mechanism, it appears that the relatively high incidence of acute complications does not translate to substantial long-term morbidity in the HDR-BT group with this algorithm.
The RTOG/EORTC morbidity score associated with HDR-BT was 0.8, indicating that this treatment modality may have a protective effect against the many radiationassociated chronic soft tissue changes observed with traditional radiation modalities. The RTOG/EORTC morbidity score with EBRT in our algorithm was 1.9. Therefore, survivors of sarcoma may be affected by late complications that contribute to morbidity identified in the morbidity score, and further study will be required to better characterize how these morbidities affect survivors' longterm function and quality of life. Although we cannot directly compare these treatments, we did characterize the long-term morbidity outcomes associated with the three treatment groups and could express this more objectively, using RTOG/EORTC morbidity scores. This scoring system has the strength of assessing morbidity through clear and objective physical findings. Furthermore, this system identifies morbidity associated with skin, subcutaneous tissues, and bone and joint function, allowing comprehensive evaluation of limb morbidity attributable to radiation treatment.
The final and main goal of this study is to evaluate whether limb-salvage surgery and HDR-BT or HDR-BT+ EBRT combination therapy results in acceptable local control in primary high-grade extremity soft tissue sarcomas for selected patients. In our study, 40% of patients in the HDR-BT and 30% in the HDR-BT+EBRT groups were surgically treated with tumor bed excisions after an unplanned excision. Studies vary regarding the efficacy of brachytherapy for local control of extremity soft tissue sarcomas, with extensive variability in tumor grade, size, depth, histologic diagnoses, margin status, and brachytherapy technique. As such, a broad range of local recurrence data exist, ranging between 18% to 78% [22, 26, 28, 42, 43, 50] for HDR-BT alone, and between 0% and 85% when brachytherapy is combined with EBRT [5, 9, 12, 19, 34, 36, 39, 45] . Large series have shown that unplanned excision is associated with an increased risk for local recurrence [47, 48] .
As such, the relatively high percentage of patients with unplanned excisions in these groups represents an additional challenge for local control. As anticipated based on the enrollment criteria, our brachytherapy group had a high rate of positive margins at the time of excision, which is associated with higher rates of local recurrence [52, 53, 62] . Tumor size is also a negative prognostic factor in the treatment of soft tissue sarcomas [30, 62] , with Kolovich et al. [30] reporting that a patient with a tumor larger than 8 cm had a 3.15-times greater chance of death. Our study population of primary nonrhabdoid high-grade extremity sarcomas is a high-risk group for local failure, owing to the narrow histologic inclusion criteria, high percentage of positive margins, unplanned excision location, and large tumor volumes. Despite the patients evaluated in our study being high-risk, the observed percentage with high-grade extremity soft tissue sarcomas with local control treated with limb-salvage surgery and HDR-BT was 82%. As would be expected, local recurrence rates were highest for the combination therapy group, which contained patients with the largest tumors and most complex relationships with surrounding neurovascular structures and/or positive margin status (10%).
This single-institution study suggests that an algorithmic approach to using HDR-BT and EBRT in the treatment of high-grade extremity soft tissue sarcomas can yield acceptable complication rates and good morbidity outcome scores and local control rates. Our results may help future, hopefully prospective, studies, to stratify treatment groups for studies of patients with nonrhabdoid high-grade extremity soft tissue sarcomas. Specifically, we believe HDR-BT is best used for patients with an anticipated close margin, a positive surgical margin, and for patients with a low likelihood for a complex soft tissue procedure. Conversely, anticipated need for secondary procedures and/or soft tissue coverage should encourage the use of EBRT alone. Finally, combination therapy should be used when the treatment volume exceeded the treatment field capacity for HDR-BT or when the catheters were used to boost a close or positive surgical margin.
